Second-line therapy for advanced liver cancer after targeted and immune treatment
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs (SHR-1701 and apatinib) for people whose liver cancer has grown or caused side effects after first-line treatment. It aims to see if this second-line therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer that cannot be surgically removed or has spread to other parts of the body.
- You've already tried a first-line regimen that combined targeted therapy (like a TKI) and immunotherapy (like a PD-1 inhibitor), and it stopped working or caused severe side effects.
- You have at least one tumor that can be measured on imaging scans (RECIST 1.1).
- Your liver function is well preserved (Child-Pugh class A, score 5-6).
- Your blood counts and liver and kidney function are within acceptable ranges (e.g., hemoglobin ≥ 90 g/L, platelets ≥ 75 x 10^9/L, bilirubin ≤ 2 times the upper limit of normal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial tests a combination of two medicines (adebrelimab and apatinib) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combo can slow down the cancer and improve outcomes.
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
This trial tests a combination of two drugs for advanced stomach, gastroesophageal junction, or colorectal cancer. The drugs work in different ways to attack cancer cells and may help slow down the disease.
Hear when a new Advanced Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.